Biotech · Private company
Fusion Pharmaceuticals Inc.
Track this companyFree. Adds Fusion Pharmaceuticals Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials42 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- [111In]-FPI-1967Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- [225Ac]-FPI-1966Phase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- FPI-2265Phase 2 · Metastatic Castration-resistant Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- vofatamabPhase 2 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- [111In]-FPI-1547 InjectionPhase 1 · Advanced Solid TumoursClinicalTrials.gov · fetched Nov 12, 2026
- [225Ac]-FPI-1434 Injection multi-dosePhase 1 · Advanced Solid TumoursClinicalTrials.gov · fetched Nov 12, 2026
- [225Ac]-FPI-1434 Injection single-dosePhase 1 · Advanced Solid TumoursClinicalTrials.gov · fetched Nov 12, 2026
- FPI-1175 InfusionPhase 1 · Advanced Solid TumoursClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 5, 2024ClinicalTrials.gov NCT06402331 · fetched Nov 12, 2026
- A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursPHASE1_PHASE2 · TERMINATED · started Apr 20, 2022ClinicalTrials.gov NCT05363605 · fetched Nov 12, 2026
- Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).PHASE2 · ACTIVE_NOT_RECRUITING · started Dec 16, 2021ClinicalTrials.gov NCT05219500 · fetched Nov 12, 2026
- A Phase 1 Study of [225Ac]-FPI-1434 InjectionPHASE1 · TERMINATED · started Jan 17, 2019ClinicalTrials.gov NCT03746431 · fetched Nov 12, 2026